SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Fritzler, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fritzler, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advances and Applications of Multiplexed Diagnostic Technologies in Autoimmune Diseases

MJ Fritzler

Department of Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada, fritzler{at}ucalgary.ca

There is a rapid proliferation of new technologies to identify an ever increasing spectrum of autoantibodies in diverse medical conditions that range from organ-specific autoimmune diseases to systemic rheumatic diseases. Although many laboratories have adopted diagnostic platforms, such as enzyme linked immunoassays (ELISAs), to improve turn around times and meet budget constraints, the prevailing evidence is that the rapid adoption of new technologies is not attended by an appropriate balance of assay sensitivity and specificity. Emerging diagnostic technologies include addressable laser bead immunoassays, microarrays in microfluidics platforms and nanobarcode particles. Although these technologies provide advantages of high-throughput, multiplexed autoantibody assays that can be coupled to other disease specific biomarkers (ie, cytokines, single nucleotide polymorphisms) there is a clear need for standardization and internal validation before they are adopted into the clinical diagnostic laboratory.

Key Words: autoantibodies • diagnosis • technologies

Lupus, Vol. 15, No. 7, 422-427 (2006)
DOI: 10.1191/0961203306lu2327oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 The Journal of RheumatologyHome page
R. JURENCAK, M. FRITZLER, P. TYRRELL, L. HIRAKI, S. BENSELER, and E. SILVERMAN
Autoantibodies in Pediatric Systemic Lupus Erythematosus: Ethnic Grouping, Cluster Analysis, and Clinical Correlations
J Rheumatol, February 1, 2009; 36(2): 416 - 421.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Hartmann, M. Schrenk, A. Dottinger, S. Nagel, J. Roeraade, T. O. Joos, and M. F. Templin
Expanding Assay Dynamics: A Combined Competitive and Direct Assay System for the Quantification of Proteins in Multiplexed Immunoassays
Clin. Chem., June 1, 2008; 54(6): 956 - 963.
[Abstract] [Full Text] [PDF]

Home page
 LupusHome page
Y Shoenfeld
Novel Aspects of Diagnostic Test: Multiple Autoantigens, New Algorithms and Revolutionary Techniques
Lupus, July 1, 2006; 15(7): 389 - 390.
[PDF]


Advertisement